<DOC>
	<DOCNO>NCT02257788</DOCNO>
	<brief_summary>PRO 140 2103 multicenter , randomize parallel group study , conduct male female adult subject infect CCR5-tropic HIV-1 .</brief_summary>
	<brief_title>PRO 140 Human Immunodeficiency Virus Infection</brief_title>
	<detailed_description>Protocol PRO 140 2103 multicenter , randomize parallel group study , conduct approximately 40 male female adult subject ( n=10/treatment group ) infect CCR5-tropic HIV-1 . Subjects randomize one four treatment group . Blood sample drug concentration , PD variable , efficacy variable obtain 59-day period follow initiation dose . Safety monitor throughout course study .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<criteria>1 . Males female , age ≥18 year 2 . Has take antiretroviral therapy ( ART ) within 12 week early screen visit 3 . Screening plasma HIV1 RNA ≥ 5,000 copies/mL 4 . CD4+ lymphocyte cell count ≥500 cells/mm3 document count less equal 250 cells/mm3 5 . Exclusive CCR5tropic virus determine determine Enhanced Sensitivity Trofile™ HIV Tropism Assay 6 . Clinically normal rest 12lead ECG screen visit 7 . Women reproductive potential must negative serum pregnancy test Late Screening Visit . Within hour prior receive first dose study drug , woman reproductive potential must negative urine pregnancy test . Male female subject must agree participate conception process agree use one barrier method contraception plus one highly reliable contraceptive method early screening visit three week last administer subcutaneous dose PRO 140 . 1 . CXCR4tropic virus , dual/mixed tropic ( R5X4 ) virus determine Enhanced Sensitivity Trofile™ HIV Tropism Assay 2 . Females pregnant , lactating , breastfeeding , plan become pregnant study 3 . Diagnosis acute viral hepatitis ( define active infection hepatitis A new diagnosis hepatitis B C within 24 week dose ) 4 . Chronic hepatitis 5 . Prior use entry , attachment , CCR5 coreceptor , fusion inhibitor , include PRO 140 , experimental approve 6 . Any immunization vaccination ( include influenza vaccine ) within 30 day prior administration study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>